Early “Developability” Assessment, Key to Success in Development Phases

3/13/2018 13:45 - 14:20

 

  • How to scientifically select a new molecular entities (NMEs) in a research leads portfolio
  • How to characterize physico-chemical properties as function of the expected Target Product Profile (TPP)
  • Rationally select polymorphism before development
  • How and when do you need to utilize enabling technologies to streamline drug development of molecule presenting limitations/weaknesses.

Philippe Lienard, CMC Discovery Coordinator, Sanofi